Tempus AI Shares Jump as Volume Surges 4.1x on 'Data Flywheel' Buzz
TEM volume surged 4.1x its 20-day average after a bullish 'Data Flywheel' article, but a 432% debt ratio and -54.8% ROE warrant caution.
signal:TEM:2026-08-19 Tempus AI Shares Jump as Volume Surges 4.1x on ‘Data Flywheel’ Buzz
Trading volume in Tempus AI (TEM) surged to 4.1x its 20-day average on August 19, a day after an August 18 article titled "Tempus AI: The Data Flywheel Has Started Spinning" began circulating and just weeks after the company posted a Q2 (quarter ended June 30, 2026) EPS surprise of +71.7%, with actual results of -$0.04 beating the -$0.1411 consensus estimate. The confluence of a sharply positive earnings surprise, a bullish narrative shift around the company's data platform, and a volume spike large enough to stand out from recent trading history makes TEM a name worth watching closely for signs of a sustained trend shift, even though the underlying business remains unprofitable on a GAAP basis.
The setup is also unfolding against a broadly risk-friendly macro backdrop: the VIX sits at a calm 14.9, the 10-year Treasury yield is flat over the past month at 4.65%, and the dollar index (DXY) has fallen 2.3% over the same period to 98.8 — a combination that has historically supported flows into higher-beta technology and healthcare-tech names like Tempus.
Key Facts
| Stock name | TEM |
|---|---|
| Ticker | TEM |
| Market | NASDAQ |
| Sector | Unclassified |
| Volume (x average) | 4.1x |
| Signal price | $61.25 |
Tempus AI operates as a healthcare technology company focused on precision medicine. Its core Tempus platform provides closed-loop, bi-directional integrations between clinicians' desktops and the company's laboratory diagnostics, analytics, and multimodal data repository, supplemented by the Hub application for NGS-based diagnostic workflows and the Lens application for life sciences and precision research. The company's diagnostics services span NGS testing, PCR profiling, and other anatomic and molecular pathology assays, including large-panel solid tumor and hematologic testing.
Recent Analyst Coverage
External analyst opinions (not investment advice): (2026-08-01)
| Strong Buy | 6 |
|---|---|
| Buy | 7 |
| Hold | 8 |
| Sell | 1 |
| Strong Sell | 1 |
Peer Companies
MEDP, CRL, RVTY, TECH, RGEN
Risk Factors
Tempus AI's balance sheet carries real weight: the debt ratio stands at a high 432%, and return on equity is deeply negative at -54.8%, underscoring that the underlying business is still burning capital rather than generating it. The EV/EBITDA multiple of -49.3x reflects negative EBITDA, meaning traditional profitability-based valuation anchors don't apply here — investors are pricing the story on growth and narrative rather than current earnings power. Insider activity adds a note of caution as well: Form 4 filings show one net insider sale and zero purchases in the past 10 days, which doesn't confirm the bullish volume signal from an internal-ownership perspective.
On the macro side, the setup benefits from a low-VIX (14.9), weak-dollar (DXY down 2.3% over the past month) environment that has generally favored risk assets, but that backdrop can reverse quickly — a stabilizing or strengthening dollar, or a pickup in the currently flat 10-year yield (4.65%), would remove one of the tailwinds currently supporting speculative, unprofitable tech names. TEM's classification as an "unclassified" industry name also means less peer-relative context is available for gauging whether this move is stock-specific or part of a broader sector rotation.
Recent Disclosures
Recent News
- 2026-08-19 Moderna Doubles, Gold Rallies To $4,500 As Dollar Sinks: Stock Market Today
- 2026-08-19 Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday
- 2026-08-18 Tempus AI: The Data Flywheel Has Started Spinning
Earnings Trend
| Fiscal Year | Revenue | Net Income |
|---|---|---|
| 2023 | $532M | $-214M |
| 2024 | $693M | $-706M |
| 2025 | $1,272M | $-245M |
Pre-Trade Checklist
| Business & competitive edge understood | ✅ Company profile summarized above |
|---|---|
| Leading sector | ⚠️ Not flagged as a leading sector |
| Good news already priced in? | ⚠️ Insufficient valuation data to judge |
| Stop-loss / take-profit set | ✅ Stop-loss -10% / first take-profit +20% set in advance |
| Exit plan if wrong | ✅ 10% trailing stop from peak; setup auto-invalidated on a break below key support |
Trade Levels
| Signal price | $61.25 |
|---|---|
| Stop-loss | $55.12 (-10% from signal price) |
| First take-profit | $73.50 (+20% from signal price) |
| Trailing stop | 10% from peak |
| Invalidation | Close back below key support ($50.61) |
With shares near the $61.25 signal price, the setup calls for watching whether the volume-driven move can build into a durable trend: a push toward the $73.50 first target (+20%) would validate the thesis, while a stop-loss at $55.12 (-10%) and a break below the $50.61 support level would invalidate it and warrant stepping aside; this remains a name to monitor rather than chase.